ABEO Abeona Therapeutics Inc.

ABEO INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Abeona Therapeutics Inc. and a Lead Plaintiff Deadline of February 14, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased PlasmaTech Biopharmaceuticals, Inc. securities between March 31, 2015 and June 19, 2015 and/or Abeona Therapeutics Inc. securities (NASDAQ:ABEO) between June 22, 2015 and December 9, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/abeona-therapeutics-inc. There is no cost or obligation to you.

According to the complaint, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the science behind Abeona’s proposed gene therapy treatment for Sanfilippo syndrome is unviable; (2) Steven H. Rouhandeh, Abeona’s Executive Chairman and Principal Executive Officer, previously worked for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks; and (3) as a result, Defendants’ statements about Abeona’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On December 12, 2016, analyst firm Mako Research published a report asserting, among other things, that Abeona’s science underpinning its gene therapy approach is unviable and that Rouhandeh previously worked in a position of authority at D. Blech & Co.—a firm named after now­convicted felon David Blech.

If you suffered a loss in Abeona you have until February 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/abeona-therapeutics-inc.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
27/01/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abeona Therapeutics Inc.

 PRESS RELEASE

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief...

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company’s corporate strategy and business development functions, as well as drive operating efficiency for the Company. “Mohamad brings a wealth of experience in strategic planning and business development,” said Vish Seshadri, Chief Executive Officer of Abeo...

 PRESS RELEASE

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVA...

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN, a first-of-its-kind, FDA-approved autologous, gene therapy is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa...

 PRESS RELEASE

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® ...

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN was administered at Lucile Packard Children’s Hospital Stanford in Palo Alto, CA. “Treating our first patient is a proud moment for Abeona and a testament ...

 PRESS RELEASE

Abeona Therapeutics® Announces New Employee Inducement Grants Under Na...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On November 30, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in...

 PRESS RELEASE

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and ...

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates - First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success - - $207.5M in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2025 expected to fund operations for over two years - CLEVELAND, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch